New York, NY (PRWEB) April 22, 2013
On April 22, Voices Against Brain Cancer (VABC), an organization dedicated to brain cancer research and advocacy, comments on an article published by Biosciencetechnology.com that discusses a new Phase 2 clinical trial that tested a new procedure for treating a somewhat rare form of brain cancer, primary CNS lymphoma, that may change the form of care for this disease.
According to the article, the trial involved “44 patients who were given a combination of high-dose chemotherapy with immune therapy, rather than the standard combination of chemotherapy with a technique known as whole-brain radiotherapy.”
The new treatment avoids whole-brain radiotherapy, which, according to the article, at high doses can “kill brain cells and lead to a progressive deterioration of the function of the nervous system in patients. Many patients die from the toxicity of the radiation as opposed to the cancer itself.” This means that the new treatment is less invasive.
The new treatment also appeared to be more effective, with most patients enrolled in the trial still doing well after a follow-up five years after treatment, according to researchers. The study suggests the new treatment is both less invasive and more effective than traditional treatment.
Primary CNS lymphoma is a deadly and devastating form of non-Hodgkin’s lymphoma, which, according to the article, is the fifth leading cause of cancer in the U.S. Approximately 1,600 Americans are diagnosed with this rare form of brain cancer each year.
Michael Klipper, chairman of VABC, is eager to see how this treatment and further innovative brain cancer treatments develop in the future. “Any breakthrough in brain cancer research excites us. It gives those suffering from this terrible disease hope and keeps all of us who are involved with this work stay that much more focused on finding truly effective treatments for brain cancer.”
These findings were originally first published in the Journal of Clinical Oncology.
VABC has a wide variety of initiatives in place for brain cancer research, awareness and support. The organization’s research grants fund cutting-edge research programs that will have a monumental impact on the diagnosis and treatment of brain cancer. VABC currently funds research at several esteemed institutions such as Brookhaven National Laboratory, Cleveland Clinic, Columbia, Cornell, Duke, Harvard, John Hopkins, Memorial Sloan-Kettering and Yale, to name a few.
VABC's mission is to find a cure for brain cancer by advancing scientific research, increasing awareness within the medical community and supporting patients, their families and caregivers afflicted with this devastating disease.
For press inquiries, please contact 5W Public Relations at 5wpr.com